Clinical trial
Clinical Characteristics, Outcomes and Quality of Life in Patients With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab After Prior Chemotherapy as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom
NCT04936399 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Clinical Characteristics, Outcomes and Quality of Life in Patients With Squamous Cell Oesophageal Carcinoma Receiving Nivolumab After Prior Chemotherapy as Part of an Early Access to Medicines Scheme (EAMS) Program in the United Kingdom
- Lead sponsor
- Bristol-Myers Squibb
- Phase
- Observational
- Overall status
- Completed
- Start date
- June 25, 2020
- Completion date
- December 3, 2021
- Enrollment
- 87 (actual)
- Sites
- 36
Conditions
As the registry lists them; a condition with its own page is linked.